










THE INVESTMENT PLAN FOR EUROPE

GRIFOLS BIOSCIENCE R&D



Research and Development into medical treatment for conditions such as Alzheimer's disease, arterial thrombolysis as well as vascular and cardiovascular surgery. Grifols is a global healthcare company focused on the development of life-saving medicines and diagnostics systems. It spends a significant portion of its annual income on R&D. The company currently employs close to 14,000 employees and is present in more than 100 countries worldwide. The EFSI investment project covers all stages of development, including pre-clinical and clinical development.

	Project promoter	Grifols SA
	Sector	Health / social / R&D
	Location	Barcelona, Spain
	Product type	EIB loan
	Financing amount under EFSI	EUR 100 million
	Total project cost	EUR 241 million
	EFSI added value	Grifols uses the EUR 100 million to finance medical research and development of treatments.
 	Economic and social impact	This investment enhances Europe's position in medical innovation.
	Signed	28 October 2015